Literature DB >> 11110414

A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

R Bilbao1, M Bustos, P Alzuguren, M J Pajares, M Drozdzik, C Qian, J Prieto.   

Abstract

We have evaluated gene transfer efficiency to tumor nodules in diethylnitrosoamine (DENA)-induced hepatocellular carcinoma (HCC) in rats using adenoviral vectors administered by three different routes: intraportal, intra-arterial and intratumoral injection. Our results showed that intraportal infusion could not transduce tumor nodules greater than 1 mm in diameter while the intra-arterial route allowed transduction of nodules up to 2-5 mm in diameter. Tumors greater than this size were resistant to transduction by intravascular route, but could be transduced by direct intratumoral injection, indicating that the obstacle preventing gene transfer to tumor cells was mainly at the level of tumor vasculature and not at the level of neoplastic cells. We have studied the extracellular matrix in tumoral lesions to assess whether nodules with different size and histological pattern have different profiles in relation to transduction efficacy. Immunohistochemical detection showed a high expression of fibronectin (FN), laminin (LN) and alpha-smooth muscle actin (alpha-SMA) in those large HCC, which were resistant to adenoviral infection. Intra-arterial infusion of vasoactive compounds (histamine, angiotensin II or nitric oxide donor nitroglycerin) before vector administration enhanced gene transfer to tumor nodules that were poorly transduced without pre-treatment. Nitroglycerin was active to enhance transduction of large tumors with trabecular or pseudoglandular histological pattern, which were impermeable to adenoviral vectors even after histamine or angiotensin treatments. Our data indicate the presence of a physical barrier between blood and neoplastic cells, which prevents transduction of the tumor by vectors given by the intravascular route. The thickness and impermeability of the barrier increases as the tumor nodule grows. Vasoactive compounds may be of value in gene therapy of liver cancer by increasing transduction efficiency by intravascularly administered vectors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110414     DOI: 10.1038/sj.gt.3301312

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

1.  Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.

Authors:  Florian Graepler; Marie-Luise Lemken; Wolfgang A Wybranietz; Ulrike Schmidt; Irina Smirnow; Christine D Gross; Martin Spiegel; Andrea Schenk; Hansjörg Graf; Ulrike A Lauer; Reinhard Vonthein; Michael Gregor; Sorin Armeanu; Michael Bitzer; Ulrich M Lauer
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention.

Authors:  Yi-Sheng Liu; Ming-Tsung Chuang; Yi-Shan Tsai; Hong-Ming Tsai; Xi-Zhang Lin
Journal:  Eur Radiol       Date:  2012-05-24       Impact factor: 5.315

3.  Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.

Authors:  Baowei Su; Arzu Cengizeroglu; Katarina Farkasova; Joana R Viola; Martina Anton; Joachim W Ellwart; Rudolf Haase; Ernst Wagner; Manfred Ogris
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

4.  A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.

Authors:  Raghothama Chaerkady; H C Harsha; Anuradha Nalli; Marjan Gucek; Perumal Vivekanandan; Javed Akhtar; Robert N Cole; Jessica Simmers; Richard D Schulick; Sujay Singh; Michael Torbenson; Akhilesh Pandey; Paul J Thuluvath
Journal:  J Proteome Res       Date:  2008-08-21       Impact factor: 4.466

5.  Intra-arterial adenoviral mediated tumor transfection in a novel model of cancer gene therapy.

Authors:  Gustavo Cabrera; Stacy L Porvasnik; Paul E DiCorleto; Maria Siemionow; Corey K Goldman
Journal:  Mol Cancer       Date:  2006-08-09       Impact factor: 27.401

6.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.

Authors:  B van Etten; T L M ten Hagen; M R de Vries; G Ambagtsheer; T Huet; A M M Eggermont
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

7.  Oncolytic adenoviruses: A thorny path to glioma cure.

Authors:  I V Ulasov; A V Borovjagin; B A Schroeder; A Y Baryshnikov
Journal:  Genes Dis       Date:  2014-12

8.  Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.

Authors:  M Verónica Lopez; Diego L Viale; Eduardo G A Cafferata; Alicia I Bravo; Cecilia Carbone; David Gould; Yuti Chernajovsky; Osvaldo L Podhajcer
Journal:  PLoS One       Date:  2008-04-08       Impact factor: 3.240

9.  Trial watch: Oncolytic viruses for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

Review 10.  Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.

Authors:  Andrew Nguyen; Louisa Ho; Yonghong Wan
Journal:  Front Oncol       Date:  2014-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.